General Electric Co (GE.N) Chief Executive Officer Jeff Immelt purchased $2.6 million of the U.S. conglomerate's shares.
| Jeff Immelt, Chairman and CEO of General Electric appears at a news conference announcing the Head Health Initiative along with the National Football League (NFL), in New York March 11, 2013. |
After a strong 2013, GE shares have declined 8.5 percent in 2014, underperforming those of industrial manufacturing rivals and the broader U.S. market.
Read Whole Story @ (Reuters)
see your liking DNDN here are some points for a potential post TY
ReplyDeleteDendreon Corporation (NASDAQ:DNDN) continues to see momentum in Provenge with strong KOL support and successful meeting with European Association of Urology (EAU). More than 70% of physicians agreed that Provenge should be used prior to Zytiga and Xtandi in mCRPC. http://www.fdaheadlines.com/dendreon-corporation-nasdaqdndn-presents-additional-data-for-provenge/#sthash.mpqQaaR5.dpuf
There seems to be broad consensus that Provenge should be first in line. The real question then is, “What should come second, Xtandi or Zytiga?” prostatesnatchers. http://blogspot.com/2014/02/xtandi-enzalutamide-star-of-10th-annual.html MARK SCHOLZ, MD & RALPH H. BLUM
Dr. Piezconka - Time to Chemotherapy Following Treatment with Sipuleucel-T: Data from PROCEED
#ASCO14 - Poster: Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED
http://ampofny.com/news/article/dr.-piezconka-time-to-chemotherapy-following-treatment-with-sipuleucel-t-data-from-proceed
However, if I am asked a slightly different question—“What type of new technology has the greatest potential for saving lives?”—my answer will always be the same for every patient: Immune therapy. MARK SCHOLZ, MD & RALPH H. BLUM prostatesnatchers.blogspot.com/2013/03/what-is-most-exciting-new-treatment-for.html